Clinical trials: Rosuvastatin
Healthy Subjects
A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults
The primary purpose of this study is to characterize the drug-drug interaction profiles of D-2570 with midazolam, digoxin, rosuvastatin, metformin, itraconazole, rifampicin, and omeprazole.
- Trial name
- NCT07875842
- Testing
- Itraconazole, Rifampicin, Omeprazole
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Healthy Male Subjects
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
This study will assess the effects of savolitinib on the pharmacokinetics (PK) of substrates of human transporters digoxin (P-gp), rosuvastatin (OATP1B1/3), metformin (OCT2, MATE1/2K), and furosemide (OAT1/3) in healthy male…
- Trial name
- NCT05768360
- Testing
- Savolitinib, Digoxin, Metformin Hydrochloride
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone
The purpose of this study is to determine effects of combination therapy with rosuvastatin and fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary lesions with intermediate stenosis in patient…
- Trial name
- NCT02232360
- Testing
- Rosuvastatin and fenofibrate, Rosuvastatin alone
- Where
- 6 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Gachon University Gil Medical Center
Assess the Periprocedural Myocardial Necrosis
ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch occlusion, intimal dissection and coronary spasm…
- Trial name
- ROMAIIReload (NCT01228227)
- Testing
- ATORVASTATIN 80 mg, ROSUVASTATIN 40 mg
- Where
- Italy
- Volunteers
- 310 people
- Sponsor
- Gennaro Sardella
Acute Coronary Syndrome, Carotid Atherosclerotic Plaque With Inflammation
Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome
Combination therapy of ezetimibe with a low-dose statin is occasionally used to avoid statin-related side effects in clinical practice among patients with atherosclerotic cardiovascular disease.
- Trial name
- NCT04056169
- Testing
- high-dose rosuvastatin, low-dose rosuvastatin plus ezetimibe
- Where
- 2 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Yuhan Corporation
HIV Infections
Study on Pharmacokinetics
The purpose of this study is to assess the effect of the coadministration of multiple doses of BMS-663068 on the systemic exposure of rosuvastatin.
- Trial name
- NCT02234882
- Testing
- Rosuvastatin, BMS-663068
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Atherosclerosis, Cardiovascular Disease
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
The purpose of this study is to investigate the added benefits of increased high-density lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering therapy guided by current guidelines, in older…
- Trial name
- NIA-Plaque (NCT00127218)
- Testing
- any statin, niacin
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Johns Hopkins University
Paroxysmal Atrial Fibrillation
Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation
The study will select all recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
- Trial name
- NCT02502110
- Testing
- rosuvastatin
- Volunteers
- 346 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Coronary Artery Disease Progression
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial
This study aim to evaluate whether intensive lipid lowering therapy may improve the clinical outcomes in coronary artery disease patients with in-stent neoatherosclerosis, in comparison with standard therapy.
- Trial name
- NCT03192579
- Testing
- EPA and high dose rosuvastatin, Standard dose rosuvastatin
- Volunteers
- 50 people
- Sponsor
- Kobe University
Healthy
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
Effects of multiple rising doses of BI 1839100 on safety, tolerability, pharmacokinetics and the effect of high-fat meal on pharmacokinetics of BI 1839100 will be assessed as well as assessing potential drug-drug interactions.
- Trial name
- NCT05738291
- Testing
- BI 1839100, midazolam, digoxin
- Where
- Netherlands
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions
Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA.
- Trial name
- NCT02962323
- Testing
- Torrent's Rosuvastatin Calcium Tablets 40 mg, Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Intracranial Arterial Stenosis
Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging
1. It is a multicenter, open-label, sing arm study to evaluate the effects of treatment of Rosuvastatin 10-20mg in volume and morphology of atherosclerotic plague by reducing LDL-C level to or less than 70mg/dl. 2.
- Trial name
- REALM (NCT02041117)
- Testing
- Rosuvastatin
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Beijing Tiantan Hospital
Adverse Events, Pharmacokinetic Variables
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.
The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.
- Trial name
- NCT00728780
- Testing
- ABT-143, ABT-335 and rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cisplatin Adverse Reaction
Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity
Cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans. Although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity and ototoxicity of the drug makes it…
- Trial name
- NCT04817904
- Testing
- Rosuvastatin 10mg
- Where
- Egypt
- Volunteers
- 65 people
- Sponsor
- Cairo University
Hypertension
Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects
An Open-label, Fixed-sequence, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety after multiple oral doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects.
- Trial name
- NCT02397538
- Testing
- Fimasartan, Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Endothelial Dysfunction, Atherosclerosis
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function
The aim of this study was to measure the effect of moderate and intensive lipid-lowering treatment with rosuvastatin on the endothelial function.
- Trial name
- NCT01223625
- Testing
- Rosuvastatin 5mg/day, Rosuvastatin 40mg/day
- Where
- Denmark
- Volunteers
- 87 people
- Sponsor
- Odense University Hospital
Chronic Periodontitis
Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis
Metformin (MF), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a favourable effect on alveolar bone.
- Trial name
- NCT03204058
- Testing
- Rosuvastatin, Metformin
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Government Dental College and Research Institute, Bangalore
Cardiovascular Disease, Endothelial Dysfunction
Effect of Homocysteine-lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease
Endothelial dysfunction is an early marker of atherosclerosis and is found in patients (pts) with coronary (CAD) and peripheral artery disease (PAD).
- Trial name
- NCT00693589
- Testing
- folic acid, vitamin B12 and B6 and rosuvastatin
- Volunteers
- 36 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.
- Trial name
- NCT05594615
- Testing
- EDP-235, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Dyslipidemia, Type 2 Diabetes
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
The goal of this clinical trial is to learn if drug CMG190303 to treat Type 2 Diabetes and Dyslipidemia in adults. It will also learn about the safety of CMG190303.
- Trial name
- NCT06772168
- Testing
- CMG190303(Dapagliflozin/Rosuvastatin)
- Where
- 24 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- CMG Pharmaceutical Co. Ltd